Page last updated: 2024-09-03

bw 245c and 1-hexadecyl-2-acetyl-glycero-3-phosphocholine

bw 245c has been researched along with 1-hexadecyl-2-acetyl-glycero-3-phosphocholine in 1 studies

Compound Research Comparison

Studies
(bw 245c)
Trials
(bw 245c)
Recent Studies (post-2010)
(bw 245c)
Studies
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)
Trials
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)
Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine)
963109,156187552

Protein Interaction Comparison

ProteinTaxonomybw 245c (IC50)1-hexadecyl-2-acetyl-glycero-3-phosphocholine (IC50)
Platelet-activating factor receptorHomo sapiens (human)0.0003

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Keery, RJ; Lumley, P1

Other Studies

1 other study(ies) available for bw 245c and 1-hexadecyl-2-acetyl-glycero-3-phosphocholine

ArticleYear
AH6809, a prostaglandin DP-receptor blocking drug on human platelets.
    British journal of pharmacology, 1988, Volume: 94, Issue:3

    Topics: 1-Methyl-3-isobutylxanthine; 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine; Adenosine Diphosphate; Adenosine-5'-(N-ethylcarboxamide); Dinoprost; Epoprostenol; Humans; Hydantoins; In Vitro Techniques; Male; Platelet Activating Factor; Platelet Aggregation; Prostaglandin D2; Prostaglandin Endoperoxides, Synthetic; Receptors, Immunologic; Receptors, Prostaglandin; Xanthenes; Xanthones

1988